Ono Pharmaceutical Co Ltd

Ono Pharmaceutical’s stock has seen a moderate increase, driven by promising cancer treatment results from its partner Merus N.V., which reported a 63% response rate and 79% overall survival rate for its Petosemtamab treatment.

Ono Pharmaceutical Co Ltd is set to announce its quarterly earnings on August 1st, with analysts predicting an 8.82% rise in sales.

Ono Pharmaceutical Co Ltd is expected to report a decline in profits, but a moderate increase in sales, when it releases its quarterly earnings on May 8th.

Ono Pharmaceutical’s quarterly earnings report shows a steady stock price of 1645 JPY, with investors awaiting the company’s next moves amidst market fluctuations.

Ono Pharmaceutical’s shares are trading at 1735.5 JPY, reflecting the complex dynamics of the pharmaceutical industry, with key valuation metrics providing insight into the company’s financial performance.